Gene Expression Profiling for Thyroid Tumor Classification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods struggle to accurately distinguish between benign and malignant thyroid tumors, particularly encapsulated follicular lesions with partial nuclear features of papillary thyroid carcinoma, leading to unnecessary aggressive treatments.
Innovation Solution
The use of gene expression profiling to identify differentially expressed genes such as ANK2, ARHGAP6, CITED 1, DIO1, and MET, which helps in distinguishing between benign, malignant, and borderline thyroid tumors by comparing RNA or protein expression levels in test samples to standard levels, using methods like microarray analysis and nucleic acid amplification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If standard histological methods are used to diagnose thyroid tumors, then the diagnostic process is simple and quick, but the accuracy is insufficient for distinguishing borderline cases
Solution Approach 1:
The patent introduces gene expression profiling as an intermediary diagnostic tool between traditional histology and aggressive treatment. By measuring expression levels of specific genes (ANK2, ARHGAP6, CITED1, DIO1, MET) in tissue samples, the method provides molecular-level information that mediates the diagnostic decision-making process for borderline thyroid tumors, resolving the uncertainty that standard histology cannot address.
Solution Approach 2:
The invention shifts the diagnostic parameters from morphological assessment (histology) to molecular expression levels (gene profiling). By quantifying the expression levels of specific genes and comparing them to established thresholds, the method transforms the diagnostic approach from subjective visual assessment to objective molecular measurement, thereby improving accuracy for borderline cases.
2Reliability
If aggressive treatment is applied to all thyroid nodules to ensure cancer detection, then sensitivity increases, but unnecessary treatments increase
Solution Approach 1:
The patent applies partial action by using gene expression profiling selectively for borderline cases rather than all thyroid nodules. The method identifies a specific subset of tumors (encapsulated follicular lesions with partial nuclear features) that require enhanced diagnostic evaluation, applying the molecular testing only where it is most needed to avoid unnecessary aggressive treatment while maintaining high sensitivity for cancer detection.
Solution Approach 2:
The diagnostic method incorporates feedback by comparing gene expression levels to established thresholds and using this information to guide treatment decisions. The expression levels of ANK2, ARHGAP6, CITED1, DIO1, and MET genes provide feedback that helps differentiate between benign, malignant, and borderline tumors, enabling clinicians to tailor treatment intensity to the actual risk level of each patient.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for accurate identification of malignant thyroid tumors with greater than 90% sensitivity and 80% specificity, reducing the need for unnecessary medical procedures by correctly classifying tumors as benign, malignant, or pre-cancerous borderline.
Implementation Method 1
comparing the test levels of expression to one or more standard or control levels of expression
Implementation Method 2
using methods like microarray analysis and nucleic acid amplification
Data Source
AI summary
The invention relates to methods and kits for detecting thyroid cancer by detecting differences in the expression of genes that are differentially expressed in thyroid cancer cells.